Tafasitamab Demonstrates Improved Clinical Benefit Among Patients With Relapsed or Refractory FL
Key Takeaways:
- Significantly improved clinical efficacy: Patients with relapsed or refractory follicular lymphoma (FL) who received tafasitamab in addition to lenalidomide plus rituximab had a higher mean progression-free survival (PFS) than those who received a placebo.
- Comparable safety profile: Adverse events (AEs) were similar between the tafasitamab and placebo groups.
- Potential therapy option: The results of this study show that the addition of tafasitamab to lenalidomide plus rituximab could be a new treatment option for patients with relapsed or refractory FL.
Lenalidomide plus rituximab is a common immunotherapy for patients with relapsed or refractory FL. Researchers conducted a study to assess the impact of adding tafasitamab to this regimen.
The study included 548 patients with relapsed or refractory FL. All were treated with lenalidomide plus rituximab; 273 patients also received tafasitamab while 275 patients received a placebo.
Efficacy and Safety of Tafasitamab
Adding tafasitamab to the drug regimen was associated with higher PFS. The tafasitamab group had a mean PFS of 22.4 months as opposed to the placebo group’s mean PFS of 13.9 months.
Patients with tafasitamab plus lenalidomide and rituximab had rates of AEs that were comparable to those taking the placebo. AEs occurred in 272 patients (99%) in the tafasitamab group and in 270 patients (99%) in the placebo group. The most common AEs were neutropenia and diarrhea.
Implications for Managed Care
According to the researchers, “The addition of tafasitamab to lenalidomide and rituximab resulted in a statistically significant and clinically meaningful improvement in progression-free survival, with an acceptable safety profile in patients with relapsed or refractory follicular lymphoma. This combination represents a potential new standard-of-care treatment.”
Reference
Sehn LH, Hübel K, Luminari S, et al. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. The Lancet. 2026;407(10524):133-146. doi:10.1016/S0140-6736(25)01778-7
